Lymphoma Treatment Market Dynamics 2021-2031
Lymphoma is a blood cancer that occurs in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. Lymphoma is of two types, namely Hodgkin and non-Hodgkin. Hodgkin lymphoma develops in the lymph nodes of the lymphatic system. Non-Hodgkin lymphoma is the common type of lymphoma and develops in related tissues of the lymphatic system and lymph nodes. The common symptoms of lymphoma are swelling of lymph nodes, fever, weight loss, night sweets, anorexia, itching, dyspnea, and fatigue. The standard tests applied for the diagnosis of lymphoma are immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing, and flow cytometry.
MARKET DYNAMICS
The government of different nations such as the U.S. and Europe has amplified their funding in R&D for the development of lymphoma treating drugs, which would further augment the growth of the lymphoma treatments market. However, the high cost of this treatment may also hamper the growth of the lymphoma treatments market. Moreover, the rise in the incidence of lymphoma throughout the globe is expected to drive the market growth.
MARKET SCOPE
The "Lymphoma Treatment Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of lymphoma treatment market with detailed market segmentation by treatment type, and treatment drug. The lymphoma treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in lymphoma treatment market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The lymphoma treatment market is segmented on the basis of treatment type, and treatment drug. Based on treatment type the market is segmented as hodgkin lymphoma and non-hodgkin lymphoma. On the basis of treatment drug, the market is categorized as adcetris, opdivo, rituxan/mabthera, imbruvica, keytruda, revlimid and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the lymphoma treatment market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lymphoma treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting lymphoma treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lymphoma treatment market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the lymphoma treatment market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lymphoma treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting lymphoma treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lymphoma treatment market in these regions.
MARKET PLAYERS
The report covers key developments in the lymphoma treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from lymphoma treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for lymphoma treatment in the global market. Below mentioned is the list of few companies engaged in the lymphoma treatment market.
The report also includes the profiles of key players in lymphoma treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Boston Scientific Corporation
- Imricor Medical Systems, Inc.
- LivaNova PLC
- Mayo Clinic US
- Medtronic plc
- MicroPort Scientific Corporation
- MRI Interventions, Inc.
- Nihon Kohden
- SCHILLER AG
- St. Jude Medical, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Lymphoma Treatments Market - By Treatment Type
1.3.2 Lymphoma Treatments Market - By Treatment Drug
1.3.3 Lymphoma Treatments Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LYMPHOMA TREATMENTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LYMPHOMA TREATMENTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LYMPHOMA TREATMENTS MARKET - GLOBAL MARKET ANALYSIS
6.1. LYMPHOMA TREATMENTS - GLOBAL MARKET OVERVIEW
6.2. LYMPHOMA TREATMENTS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. LYMPHOMA TREATMENTS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT TYPE
7.1. OVERVIEW
7.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
7.3. HODGKIN LYMPHOMA
7.3.1. Overview
7.3.2. Hodgkin Lymphoma Market Forecast and Analysis
7.4. NON-HODGKIN LYMPHOMA
7.4.1. Overview
7.4.2. Non-Hodgkin Lymphoma Market Forecast and Analysis
8. LYMPHOMA TREATMENTS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT DRUG
8.1. OVERVIEW
8.2. TREATMENT DRUG MARKET FORECASTS AND ANALYSIS
8.3. ADCETRIS
8.3.1. Overview
8.3.2. Adcetris Market Forecast and Analysis
8.4. OPDIVO
8.4.1. Overview
8.4.2. Opdivo Market Forecast and Analysis
8.5. RITUXAN/MABTHERA
8.5.1. Overview
8.5.2. Rituxan/MabThera Market Forecast and Analysis
8.6. IMBRUVICA
8.6.1. Overview
8.6.2. Imbruvica Market Forecast and Analysis
8.7. KEYTRUDA
8.7.1. Overview
8.7.2. Keytruda Market Forecast and Analysis
8.8. REVLIMID
8.8.1. Overview
8.8.2. Revlimid Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis
9. LYMPHOMA TREATMENTS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Lymphoma Treatments Market Overview
9.1.2 North America Lymphoma Treatments Market Forecasts and Analysis
9.1.3 North America Lymphoma Treatments Market Forecasts and Analysis - By Treatment Type
9.1.4 North America Lymphoma Treatments Market Forecasts and Analysis - By Treatment Drug
9.1.5 North America Lymphoma Treatments Market Forecasts and Analysis - By Countries
9.1.5.1 United States Lymphoma Treatments Market
9.1.5.1.1 United States Lymphoma Treatments Market by Treatment Type
9.1.5.1.2 United States Lymphoma Treatments Market by Treatment Drug
9.1.5.2 Canada Lymphoma Treatments Market
9.1.5.2.1 Canada Lymphoma Treatments Market by Treatment Type
9.1.5.2.2 Canada Lymphoma Treatments Market by Treatment Drug
9.1.5.3 Mexico Lymphoma Treatments Market
9.1.5.3.1 Mexico Lymphoma Treatments Market by Treatment Type
9.1.5.3.2 Mexico Lymphoma Treatments Market by Treatment Drug
9.2. EUROPE
9.2.1 Europe Lymphoma Treatments Market Overview
9.2.2 Europe Lymphoma Treatments Market Forecasts and Analysis
9.2.3 Europe Lymphoma Treatments Market Forecasts and Analysis - By Treatment Type
9.2.4 Europe Lymphoma Treatments Market Forecasts and Analysis - By Treatment Drug
9.2.5 Europe Lymphoma Treatments Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Lymphoma Treatments Market
9.2.5.1.1 Germany Lymphoma Treatments Market by Treatment Type
9.2.5.1.2 Germany Lymphoma Treatments Market by Treatment Drug
9.2.5.2 France Lymphoma Treatments Market
9.2.5.2.1 France Lymphoma Treatments Market by Treatment Type
9.2.5.2.2 France Lymphoma Treatments Market by Treatment Drug
9.2.5.3 Italy Lymphoma Treatments Market
9.2.5.3.1 Italy Lymphoma Treatments Market by Treatment Type
9.2.5.3.2 Italy Lymphoma Treatments Market by Treatment Drug
9.2.5.4 Spain Lymphoma Treatments Market
9.2.5.4.1 Spain Lymphoma Treatments Market by Treatment Type
9.2.5.4.2 Spain Lymphoma Treatments Market by Treatment Drug
9.2.5.5 United Kingdom Lymphoma Treatments Market
9.2.5.5.1 United Kingdom Lymphoma Treatments Market by Treatment Type
9.2.5.5.2 United Kingdom Lymphoma Treatments Market by Treatment Drug
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Lymphoma Treatments Market Overview
9.3.2 Asia-Pacific Lymphoma Treatments Market Forecasts and Analysis
9.3.3 Asia-Pacific Lymphoma Treatments Market Forecasts and Analysis - By Treatment Type
9.3.4 Asia-Pacific Lymphoma Treatments Market Forecasts and Analysis - By Treatment Drug
9.3.5 Asia-Pacific Lymphoma Treatments Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Lymphoma Treatments Market
9.3.5.1.1 Australia Lymphoma Treatments Market by Treatment Type
9.3.5.1.2 Australia Lymphoma Treatments Market by Treatment Drug
9.3.5.2 China Lymphoma Treatments Market
9.3.5.2.1 China Lymphoma Treatments Market by Treatment Type
9.3.5.2.2 China Lymphoma Treatments Market by Treatment Drug
9.3.5.3 India Lymphoma Treatments Market
9.3.5.3.1 India Lymphoma Treatments Market by Treatment Type
9.3.5.3.2 India Lymphoma Treatments Market by Treatment Drug
9.3.5.4 Japan Lymphoma Treatments Market
9.3.5.4.1 Japan Lymphoma Treatments Market by Treatment Type
9.3.5.4.2 Japan Lymphoma Treatments Market by Treatment Drug
9.3.5.5 South Korea Lymphoma Treatments Market
9.3.5.5.1 South Korea Lymphoma Treatments Market by Treatment Type
9.3.5.5.2 South Korea Lymphoma Treatments Market by Treatment Drug
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Lymphoma Treatments Market Overview
9.4.2 Middle East and Africa Lymphoma Treatments Market Forecasts and Analysis
9.4.3 Middle East and Africa Lymphoma Treatments Market Forecasts and Analysis - By Treatment Type
9.4.4 Middle East and Africa Lymphoma Treatments Market Forecasts and Analysis - By Treatment Drug
9.4.5 Middle East and Africa Lymphoma Treatments Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Lymphoma Treatments Market
9.4.5.1.1 South Africa Lymphoma Treatments Market by Treatment Type
9.4.5.1.2 South Africa Lymphoma Treatments Market by Treatment Drug
9.4.5.2 Saudi Arabia Lymphoma Treatments Market
9.4.5.2.1 Saudi Arabia Lymphoma Treatments Market by Treatment Type
9.4.5.2.2 Saudi Arabia Lymphoma Treatments Market by Treatment Drug
9.4.5.3 U.A.E Lymphoma Treatments Market
9.4.5.3.1 U.A.E Lymphoma Treatments Market by Treatment Type
9.4.5.3.2 U.A.E Lymphoma Treatments Market by Treatment Drug
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Lymphoma Treatments Market Overview
9.5.2 South and Central America Lymphoma Treatments Market Forecasts and Analysis
9.5.3 South and Central America Lymphoma Treatments Market Forecasts and Analysis - By Treatment Type
9.5.4 South and Central America Lymphoma Treatments Market Forecasts and Analysis - By Treatment Drug
9.5.5 South and Central America Lymphoma Treatments Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Lymphoma Treatments Market
9.5.5.1.1 Brazil Lymphoma Treatments Market by Treatment Type
9.5.5.1.2 Brazil Lymphoma Treatments Market by Treatment Drug
9.5.5.2 Argentina Lymphoma Treatments Market
9.5.5.2.1 Argentina Lymphoma Treatments Market by Treatment Type
9.5.5.2.2 Argentina Lymphoma Treatments Market by Treatment Drug
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LYMPHOMA TREATMENTS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT LABORATORIES
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ABIOGEN PHARMA S.P.A.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. AETERNA ZENTARIS, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BRISTOL-MYERS SQUIBB COMPANY,
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. CELGENE CORPORATION
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ELI LILLY AND COMPANY
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. F. HOFFMANN-LA ROCHE LTD.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. JOHNSON AND JOHNSON
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. MERCK AND CO., INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SEATTLE GENETICS, INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Abbott Laboratories
2. ABIOGEN PHARMA S.p.A.
3. Aeterna Zentaris, Inc.
4. Bristol-Myers Squibb Company,
5. Celgene Corporation
6. Eli Lilly and Company
7. F. Hoffmann-La Roche Ltd.
8. Johnson & Johnson
9. Merck & Co., Inc.
10. Seattle Genetics, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For